Drug intelligence / Profile preview

BI-4659

Development stage: Unknown
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: None (in Vitro Research Use Only)

Overview

BI-4659 is a potent and selective small molecule inhibitor of ALK5, also known as TGFβ receptor I. It inhibits ALK5 with an IC50 of 19 nM and blocks the phosphorylation of SMAD2 and SMAD3 in cells. The compound demonstrates good selectivity against a broad panel of other kinases and is primarily used as an in vitro research tool to study TGFβ signaling pathways[1][2][3][4][5]. There are no indications that it has been developed for clinical or therapeutic use.

Other names: (Z)-3-(((4-((dimethylamino)methyl)phenyl)amino)(phenyl)methylene)-N-ethyl-2-oxoindoline-6-carboxamide

Targets

TGFBR1

Beyond the preview

Go deeper on BI-4659.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI-4659.

Explore the full profile